Alnylam Pharmaceuticals (NASDAQ:ALNY) Downgraded by Wall Street Zen to “Hold”

Alnylam Pharmaceuticals (NASDAQ:ALNY) was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued to investors on Saturday.

Several other analysts also recently commented on ALNY. Royal Bank Of Canada decreased their price objective on shares of Alnylam Pharmaceuticals from $500.00 to $465.00 and set an “outperform” rating on the stock in a research report on Tuesday, January 20th. Bank of America reaffirmed a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Thursday, February 12th. Freedom Capital upgraded Alnylam Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, February 17th. Truist Financial decreased their price target on Alnylam Pharmaceuticals from $535.00 to $530.00 and set a “buy” rating on the stock in a report on Thursday, January 8th. Finally, Leerink Partners lowered their target price on shares of Alnylam Pharmaceuticals from $370.00 to $351.00 and set a “market perform” rating on the stock in a report on Monday, December 15th. One research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $468.84.

Alnylam Pharmaceuticals Trading Up 0.3%

Shares of NASDAQ:ALNY opened at $312.17 on Friday. The stock has a 50 day moving average of $335.41 and a 200 day moving average of $405.36. The company has a market cap of $41.40 billion, a PE ratio of 182.56 and a beta of 0.36. Alnylam Pharmaceuticals has a 12-month low of $205.87 and a 12-month high of $495.55. The company has a current ratio of 2.76, a quick ratio of 2.71 and a debt-to-equity ratio of 1.28.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, February 12th. The biopharmaceutical company reported $1.25 EPS for the quarter, missing analysts’ consensus estimates of $1.43 by ($0.18). Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.The firm had revenue of $1.10 billion for the quarter, compared to the consensus estimate of $1.16 billion. During the same quarter in the previous year, the business posted ($0.65) EPS. Alnylam Pharmaceuticals’s revenue was up 84.9% on a year-over-year basis. As a group, equities research analysts expect that Alnylam Pharmaceuticals will post -1.7 EPS for the current year.

Insider Activity at Alnylam Pharmaceuticals

In other news, EVP Pushkal Garg sold 2,242 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Friday, February 13th. The shares were sold at an average price of $310.08, for a total transaction of $695,199.36. Following the completion of the sale, the executive vice president owned 24,848 shares of the company’s stock, valued at approximately $7,704,867.84. The trade was a 8.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Kevin Joseph Fitzgerald sold 2,290 shares of the business’s stock in a transaction that occurred on Tuesday, January 13th. The shares were sold at an average price of $370.33, for a total value of $848,055.70. Following the completion of the sale, the executive vice president owned 21,264 shares of the company’s stock, valued at $7,874,697.12. The trade was a 9.72% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 53,923 shares of company stock valued at $18,072,087. 1.50% of the stock is owned by insiders.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Brighton Jones LLC purchased a new stake in Alnylam Pharmaceuticals in the fourth quarter worth about $243,000. Geneos Wealth Management Inc. increased its position in Alnylam Pharmaceuticals by 372.3% during the 1st quarter. Geneos Wealth Management Inc. now owns 222 shares of the biopharmaceutical company’s stock valued at $60,000 after purchasing an additional 175 shares during the period. Cetera Investment Advisers increased its position in Alnylam Pharmaceuticals by 23.3% during the 2nd quarter. Cetera Investment Advisers now owns 9,888 shares of the biopharmaceutical company’s stock valued at $3,224,000 after purchasing an additional 1,871 shares during the period. Ensign Peak Advisors Inc raised its holdings in shares of Alnylam Pharmaceuticals by 24.5% in the 2nd quarter. Ensign Peak Advisors Inc now owns 100,209 shares of the biopharmaceutical company’s stock valued at $32,677,000 after purchasing an additional 19,730 shares in the last quarter. Finally, Prudential PLC raised its holdings in shares of Alnylam Pharmaceuticals by 100.9% in the 2nd quarter. Prudential PLC now owns 4,112 shares of the biopharmaceutical company’s stock valued at $1,341,000 after purchasing an additional 2,065 shares in the last quarter. Institutional investors own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.